Phase 3
N=18
Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation
Adrenal Tumors
Bottom Line
View on ClinicalTrials.gov: NCT00997594 ↗Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Feb 2011
Primary outcome: Primary: Increase in Catecholamine
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Radiofrequency ablation (Procedure)
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- Mie University
- Primary completion
- Oct 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Increase in Catecholamine |
— | — |
| PRIMARY Serum Cathecholamine Levels |
— | — |
| PRIMARY Number of Participants With Hypertension During Adrenal or Non-adrenal Radiofrequency Ablation |
6; 1 | <0.05 sig |
| SECONDARY Increase in Cortisol |
— | — |
Summary
The purpose of this study is to evaluate changes in adrenal hormones during adrenal radiofrequency (RF) ablation.
Eligibility Criteria
Inclusion Criteria
- Unresectable adrenal tumor which will be treated by radiofrequency (RF)ablation
- Blood pressure is 140mmHg or less before RF ablation
- Age of 20-years or more
- Performance status of 0 or 1
- Agreement from the patient
Exclusion Criteria
- Platelet count of 50, 000/mm^3 or International normalized ratio (INR)>1.5
Data sourced from ClinicalTrials.gov (NCT00997594). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.